IRME · As filed with the SEC
IR-Med income statement, by fiscal year
The statement as IR-Med presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 |
|---|---|---|---|---|
| Research and development expenses | ||||
| Expenses incurred | 1,178 | — | — | — |
| Less- government grants | (468) | — | — | — |
| Research and development expenses, net | 710 | 2,061 | 1,885 | 1,419 |
| Marketing Expense | 220 | 822 | 759 | 888 |
| Selling, General and Administrative Expense | 1,011 | 2,028 | 2,118 | 1,368 |
| Total operating loss | 1,941 | 4,911 | 4,762 | 3,675 |
| Other income | (48) | — | — | — |
| Financial expenses (income), net | 6 | (2) | (28) | 41 |
| Loss for the year | 1,899 | 4,909 | 4,734 | 3,716 |
| Basic and dilutive loss per common stock (in dollars) | — | — | — | (0.06) |
| Earnings Per Share (Basic) | (0.03) | (0.07) | (0.07) | — |
| Earnings Per Share (Diluted) | (0.03) | (0.07) | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.